New technology for manufacturing radioisotopes for cancer diagnostic imaging

18 September 2008

New technology developed at the Delft University of Technology in the Netherlands could prevent global shortages of radio isotopes for cancer diagnosis, according to an article by Prof. Bert Wolterbeek of Delft University of Technology’s Reactor Institute Delft (RID) in the university's journal Delta.

The shortage of radioisotopes made global headlines recently. Hospitals are facing a shortage of radioisotopes which means that patients will have to wait longer for cancer diagnosis (see MTB Europe article). Only a handful of reactors around the world manufacture the isotope, technetium-99m, which is used to treat about forty million patients annually. Three of these reactors are currently unable to supply any due to maintenance work, including Europe’s most important: the Dutch reactor in Petten.

Additional isotope manufacturing would reduce the risk of shortages considerably. The current process requires enriched uranium, for which manufacturers need a special permit due to nuclear non-proliferation treaties.

Prof. Bert Wolterbeek of the RID is working on a radical solution to this problem. He is developing a method for producing the sought-after isotope without uranium. If these experiments prove to be applicable in an industrial environment, many more factories could manufacture the material.

"Technetium-99m, the material in question, is currently made by highly enriched uranium fission,” Prof. Wolterbeek explains. "One of the products created is radioactive molybdenum-99, the raw material for technetium-99m. Manufacturers supply this molybdenum to hospitals secured in rods. A hospital can ‘harvest’ the technetium-99m isotope from a rod for a week as the molybdeen-99 slowly decays into technetium-99m."

Yet molybdenum-99 can also be manufactured from molybdenum-98, a stable isotope made of natural molybdenum, a material which mining companies already extract from the ground. Prof. Wolterbeek has patented a technique in which he bombards this raw material with neutrons in order to make molybdenum-99.

The molybdenum atoms are not just ‘activated’ by the neutron bombardment, but are also separated from the surrounding atoms by the energy transfer. The resultant molybdenum-99 can then be dissolved in water. This means that the isotope can be produced in highly concentrated form. And this aspect is crucial. Prof. Wolterbeek explains: "The activity concentration of the radioactive material needs to be high, otherwise patients will be given too high a chemical dose to form a clear radiation image."

Prof. Wolterbeek wishes to hold larger-scale tests in conjunction with Urenco. The head of the Stable Isotopes department at this reprocessing company, Charles Mol, envisages the technology from Delft University of Technology being used to open up a "highly interesting market".

In his view, scientists around the globe are desperately searching for alternative manufacturing methods as the use of enriched uranium will cease at some point due to nuclear non-proliferation treaties. "Another reason," he says, "is that the current manufacturing process produces a huge amount of radioactive waste. And any alternative method using low-enriched uranium could produce even more waste."

The original article (in Dutch only):

To top